Table 1. Synopsis of results of published studies investigating the potential of circulating miRNAs as biomarkers of prostate cancer.
Study design | Upregulated miRNAs | Downregulated miRNAs | Sample type | Method | Patient numbers | Reference |
---|---|---|---|---|---|---|
Cancer vs benign |
100, 125b, 141, 143, 296 |
|
Serum |
qRT-PCR |
25 metastatic PCa vs 25 controls |
Mitchell et al, 2008 |
|
16, 92a, 103, 107, 197, 34b, 328, 485-3p, 486-5p, 92b, 574-3p, 636, 640, 766, 885-5p |
|
Serum |
MiR microarray |
5 PCa vs 8 controls (other cancers tested) |
Lodes et al, 2009 |
|
221 |
|
Plasma |
qRT-PCR |
28 PCa vs 20 controls |
Zheng et al, 2011 |
|
141, 298, 346, 375 |
|
Serum |
qRT-PCR |
25 metastatic PCa vs 25 controls |
Selth et al, 2012 |
|
346, 622, 940, 1285 |
let-7e, let-7c |
Plasma |
Illumina miR microarray |
25 PCa vs 17 BPH, then validation in 80 PCa, 44 BPH and 54 HI |
Chen et al, 2012 |
|
375, 141 |
181a-2 |
Plasma |
qRT-PCR |
78 PCa vs 28 controls, then 16 metastatic vs 55 non-metastatic |
Bryant et al, 2012 |
Localised cancer vs metastatic cancer |
9*, 141, 200b, 375, 516a |
|
Serum |
qRT-PCR |
7 metastatic PCa vs 14 localised PCa |
Brase et al, 2011 |
|
21 |
|
Serum |
qRT-PCR |
50 PCa (20 localised, 20 ADPC, 10 HRPC) vs 6 BPH |
Zhang et al, 2011 |
|
375, 141 |
181a-2 |
Plasma |
qRT-PCR |
78 PCa vs 28 controls, then 16 metastatic vs 55 non-metastatic |
Bryant et al, 2012 |
Cancer at different stage/risks vs benign |
21, 221 |
|
Plasma |
qRT-PCR |
51 PCa (18 localised, 8 locally advanced, 25 metastatic) vs 20 HI |
Yaman Agaoglu et al, 2011 |
|
93, 106a, 874, 1207 |
24, 26b, 30c, 223 |
Serum |
Multiplexed qRT-PCR |
36 PCa (12 low risk, 12 medium risk, 12 high risk) vs 12 controls |
Moltzahn et al, 2011 |
|
26a, 195, Let7i, 16 |
|
Serum |
qRT-PCR |
45 (37 localised, 8 metastatic) PCa vs 38 controls (18 BPH, 20 HI) |
Mahn et al, 2011 |
20a, 21 | Plasma | qRT-PCR | 82 PCa assessing association with CAPRA score | Shen et al, 2012 |
Abbreviations: ADPC=androgen-dependent prostate cancer; HRPC=hormone refractory prostate cancer; BPH=benign prostatic hypertrophy; HI= healthy individuals; PCa=prostate cancer; qRT-PCR=quantitative real-time PCR; miR=microRNA; CAPRA=Cancer of the Prostate Risk Assessment. *Where one hairpin miR precursor gives rise to two mature miRs, one from each arm, an asterisk is used to denote the least predominant form.